Vext Science, Inc.

CNSX:VEXT Stock Report

Market Cap: CA$48.2m

Vext Science Valuation

Is VEXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VEXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VEXT (CA$0.2) is trading below our estimate of fair value (CA$3.87)

Significantly Below Fair Value: VEXT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VEXT?

Key metric: As VEXT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VEXT. This is calculated by dividing VEXT's market cap by their current revenue.
What is VEXT's PS Ratio?
PS Ratio1x
SalesUS$33.33m
Market CapUS$34.24m

Price to Sales Ratio vs Peers

How does VEXT's PS Ratio compare to its peers?

The above table shows the PS ratio for VEXT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
HASH Simply Solventless Concentrates
6.8xn/aCA$53.2m
FFNT 4Front Ventures
0.4xn/aCA$41.2m
XLY Auxly Cannabis Group
0.4xn/aCA$45.0m
MDP Medexus Pharmaceuticals
0.4x11.0%CA$52.3m
VEXT Vext Science
1x34.6%CA$48.2m

Price-To-Sales vs Peers: VEXT is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does VEXT's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$89.06m
ACRG.A.U Acreage Holdings
0.1xn/aUS$26.82m
TIUM.U Cansortium
0.2xn/aUS$24.16m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
VEXT 1.0xIndustry Avg. 0.8xNo. of Companies24PS012345+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VEXT is expensive based on its Price-To-Sales Ratio (1x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is VEXT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VEXT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: VEXT is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VEXT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.20
CA$0.67
+241.9%
30.2%CA$0.95CA$0.50n/a3
Nov ’25CA$0.18
CA$0.67
+260.4%
30.2%CA$0.95CA$0.50n/a3
Oct ’25CA$0.23
CA$0.60
+160.9%
18.0%CA$0.75CA$0.50n/a3
Sep ’25CA$0.23
CA$0.60
+160.9%
18.0%CA$0.75CA$0.50n/a3
Aug ’25CA$0.25
CA$0.63
+150.0%
12.0%CA$0.75CA$0.55n/a4
Jul ’25CA$0.23
CA$0.63
+175.4%
13.4%CA$0.75CA$0.55n/a3
Jun ’25CA$0.24
CA$0.63
+158.5%
13.4%CA$0.75CA$0.55n/a3
May ’25CA$0.32
CA$0.73
+132.8%
3.2%CA$0.75CA$0.70n/a3
Apr ’25CA$0.28
CA$0.73
+161.9%
3.2%CA$0.75CA$0.70n/a3
Mar ’25CA$0.29
CA$0.72
+145.8%
3.4%CA$0.75CA$0.70n/a2
Feb ’25CA$0.38
CA$0.72
+93.3%
3.4%CA$0.75CA$0.70n/a2
Jan ’25CA$0.29
CA$0.72
+150.0%
3.4%CA$0.75CA$0.70n/a2
Dec ’24CA$0.27
CA$0.75
+183.0%
5.4%CA$0.80CA$0.70n/a3
Nov ’24CA$0.28
CA$0.87
+204.1%
10.9%CA$1.00CA$0.80CA$0.183
Oct ’24CA$0.34
CA$0.87
+151.2%
10.9%CA$1.00CA$0.80CA$0.233
Sep ’24CA$0.24
CA$0.87
+253.7%
10.9%CA$1.00CA$0.80CA$0.233
Aug ’24CA$0.26
CA$1.05
+311.8%
14.0%CA$1.25CA$0.90CA$0.253
Jul ’24CA$0.26
CA$1.05
+303.8%
14.0%CA$1.25CA$0.90CA$0.233
Jun ’24CA$0.27
CA$1.05
+296.2%
14.0%CA$1.25CA$0.90CA$0.243
May ’24CA$0.28
CA$1.30
+356.1%
21.8%CA$1.50CA$0.90CA$0.323
Apr ’24CA$0.26
CA$1.15
+342.3%
31.0%CA$1.50CA$0.70CA$0.284
Mar ’24CA$0.28
CA$1.21
+325.4%
35.3%CA$1.75CA$0.70CA$0.294
Feb ’24CA$0.28
CA$1.24
+350.0%
33.2%CA$1.75CA$0.70CA$0.384
Jan ’24CA$0.24
CA$1.24
+415.6%
33.2%CA$1.75CA$0.70CA$0.294
Dec ’23CA$0.25
CA$1.24
+395.0%
33.2%CA$1.75CA$0.70CA$0.274
Nov ’23CA$0.28
CA$1.46
+413.2%
40.2%CA$2.25CA$0.70CA$0.284

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Medexus Pharmaceuticals

CA$52.3m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.12

7D

-2.3%

1Y

22.5%

Verano Holdings

CA$845.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.37

7D

-12.5%

1Y

-60.7%

Cresco Labs

CA$868.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CL

CA$1.97

7D

13.9%

1Y

-19.6%